Abstract Fungal endocarditis (FE) is an uncommon disease, and while accounting for only 1.3-6% of all cases of infectious endocarditis, it carries a high mortality risk. Although Candida albicans represents the main etiology of FE, C. parapsilosis is the most common non-albicans species. We report the case of a 32-year-old man with a history of prior intravenous drug (IVD) use hospitalized with endocarditis due to C. parapsilosis and review all 71 additional cases documented in the literature. A retrospective analysis of the 72 C. parapsilosis cases compared to 52 recently reviewed cases of C. albicans endocarditis was conducted to identify organism-specific clinical peculiarities. The most common predisposing factor for C. parapsilosis endocarditis (41/72; 57.4%) involved prosthetic valves followed by IVD use (12/72; 20%). Peripheral embolic and/or hemorrhagic events occurred in 28/64 (43.8%) patients, mostly in cerebral and lower limb territories. Overall mortality was 41.7%. Combined surgical and clinical treatment was associated with a lower mortality. Few patients received the newer antifungal agents, and it would appear that more experience is required for their use in the treatment of C. parapsilosis endocarditis.
Introduction
Although fungal endocarditis (FE) accounts for only 1.3-6% of all infective endocarditis cases, it carries a high mortality risk and has increased in incidence over the last two decades [1, 2] . The latter may be explained by improved diagnostic methods, a greater exposure to medical therapies that predispose to fungal infection, an increase in the incidence of intravenous drug (IVD) use and a more frequent use of invasive procedures for diagnosis and therapy [1, 3] . Fungal endocarditis is associated with a higher incidence of embolic events than bacterial endocarditis. An additional diagnostic challenge is that some common clinical signs and symptoms of endocarditis, including the presence of cardiac murmurs, may be absent [4] .
The incidence of invasive candidiasis has increased during the past years [5] , with Candida species being the most common agents involved in fungal endocarditis, followed by Aspergillus species. In a review of 152 cases of FE, Candida spp. was responsible for 94.1% of yeast endocarditis and Aspergillus spp. for 71.8% of mold endocarditis [1] . Among yeast-related endocarditis, C. albicans was the most frequent strain isolated (46%), followed by C. parapsilosis (17%). The latter was the most common pathogen isolated in IVD users [4] . Candida parapsilosis is also associated with nosocomial infections related to vascular devices, which may be explained in part by its ability to produce a biofilm on foreign bodies and catheters [6] .
We report here a case of relapsing C. parapsilosis endocarditis in an IVD user-patient and review the additional 71 cases published in the literature. A comparison of outcome differences with 52 C. albicans endocarditis cases was also conducted with the aim of identifying organism-specific clinical peculiarities.
Materials and methods
We conducted an OVID-MEDLINE search without language restriction from January 1968 through October 2006 to identify cases published in any language. The keywords "Candida parapsilosis", "endocarditis" and "fungal endocarditis" were used. Additional references were retrieved from reviews on the topic. Only reports with sufficient information on epidemiological and clinical data for patients over 16 years old were included. The review was also restricted to cases of "definite infective endocarditis" according to the modified Duke's criteria [7] .
To evaluate potential clinical and epidemiological disagreement, the 72 cases of C. parapsilosis endocarditis were compared with 52 cases of C. albicans endocarditis recently reviewed [1] .
Collected data were recorded in a database especially designed for the study. Analyses were performed by chisquare test, Fisher's exact test, and Student's t test, as appropriate. Two-sided tests were used and p<0.05 was considered to be statistically significant. In the multivariate analysis, the dependent variable was mortality, and only variables with a p<0.2 in terms of outcome were included in a stepwise logistic regression model. Calculations were made using the EPIINFO statistical program, ver. 3.3.2 (Centers for Disease Control and Prevention, Atlanta, GA).
Case report
A 32-year-old man with a history of prior IVD use was hospitalized with acute thromboembolic stroke and C. parapsilosis candidemia. Transoesophageal echocardiography (TEE) revealed a 6-mm-sized floating vegetation in the aortic valve. In view of the intermediary susceptibility to fluconazole presented by the blood isolate of C. parapsilosis (MIC4 mg/l), combined therapy with caspofungin [70 mg intravenous (i.v.) as first day loading dose, followed by 50 mg/day i.v.] and voriconazole [800 mg daily (p.o.) first day loading dose, followed by 400 mg/d p.o.] was administered for 12 weeks. The patient refused a surgical aortic valve replacement and was discharged with a proposed suppressive therapy of voriconazole (400 mg/day p.o), but was subsequently lost to follow-up. Three months after hospital discharge, he was re-hospitalized due to an episode of thromboembolic ischemic stroke linked to relapsed C. parapsilosis endocarditis. The patient acknowledged noncompliance to the voriconazole treatment previously prescribed. Voriconazole (400 mg/day p.o.) was restarted. A new TEE showed a vegetation in the aortic valve associated with a perforation and a mycotic aneurysm in the right coronary cuspid. A moderate to severe valve insufficiency was also found. In view of these findings and the severe hemodynamic compromise, the decision was taken to replace the aortic valve by a porcine xenograft valve (Schilling N°25). The post-operative period was uneventful, and the patient was discharged from the hospital under voriconazole therapy (400 mg/day p.o.) -and again was lost to follow-up. One year following surgery, the patient was re-admitted with severe cardiac failure due to severe aortic insufficiency associated with paravalvar leak. He admitted to having followed the antifungal treatment for only 4 months following his last discharge. Blood cultures yielded C. parapsilosis once again, and a TEE revealed vegetations in the aortic prosthetic valve. The patient died suddenly two days after admission. The authorization to perform the autopsy was not given.
Results
Including our own case, we retrieved a total of 80 cases of endocarditis due to C. parapsilosis. Of these, 72 met the inclusion criteria (Appendix). Most cases were published prior to the availability of the newer antifungal compounds, such as echinocandins and second-generation triazoles.
Clinical presentation, risk factors and complications
Of the 72 patients meeting the inclusion criteria of this review, 71% (51/72) were male, and the mean age was 48.73 years (±15.8 years). Forty-one (57%) patients had isolated prosthetic valve involvement, and 31 (48.6%) had isolated native valve involvement; in four subjects, both native and prosthetic (relapsing infection) valve involvement occurred. Globally, the most frequent predisposing factor was prior cardiac surgery for valve replacement (57%) ( Table 1) . Late-onset infection, defined here as 6 months following surgery, occurred in 21/33 (63.3%) patients with prosthetic valve involvement for whom data were available. The second most frequent predisposing factor was IVD use (12/72 patients; 16.6%). Eleven of the 72 patients (15.2%) presented simultaneously with more than one predisposing factor. An absence of predisposing factors was observed in only 4/72 (5.6%) patients.
Data on embolic or hemorrhagic complications were available for 64 (88.8%) of the 72 patients. Of these, 28 (43.8%) presented complications, with the most common sites being the lower limbs (ten; 35.7%) and the brain (six; 21.4%), followed by the lung (three; 10.7%) and the upper limbs (two; 7.1%). Seven (25%) of 28 patients presented intracranial hemorrhage, probably secondary to mycotic aneurysms. Table 1 summarizes the characteristics of the 52 reported cases of C. albicans [1] and the 72 cases of C. parapsilosis endocarditis. The latter showed a trend towards a more frequent history of prior parenteral nutrition and valvular disease.
Therapy and outcome
Single, combined or sequential medical antifungal therapy was received by 28 (38.0%), 25 (34.7%) and 16 (22.2%) patients, respectively. Amphotericin B deoxycholate was the most frequently prescribed antifungal drug in 41 patients (56.9%), followed by 5-fluocytosine (23 patients; 31.9%) and fluconazole (20 patients; 27.7%). Other antifungal treatments were lipid formulations of amphotericin B (six patients; 8.3%) and miconazole and ketoconazole (five patients; 6.9%). Five patients were treated with the newer antifungal drugs caspofungin (three patients; 4.1%) and voriconazole (two patients; 2.7%). Medical treatment was not specified in two cases (2.7%). Combined surgical and medical treatment was performed in 42/72 (58.3%) patients. Interestingly, surgical therapy was more commonly performed in native valve patients (72.4%) than in patients with prostheses [45.7%; Odds Ratio (OR) 3.1; 95% confidence interval (CI) 1.0-8.9; p=0.05].
Neither mean age nor gender was associated with outcome. A trend was observed toward a higher mortality among patients with C. parapsilosis endocarditis less than 65 years (OR 3.18; 95%CI 0.85-11.83; p=0.07). Of note, this was restricted to patients that underwent cardiac surgery (OR 5.2; 95%CI 0.81-32.98; p=0.08).
The mortality rate was lower among patients undergoing adjunctive surgical therapy (33.3%) than among those treated only with antifungals (53.3%), but the difference was not statistically significant (OR 0.4; 95%CI 0.2-1.1; p=0.14). Surgery was not related to a lower incidence of embolic and/or hemorrhagic complications, which were observed in 43.9% of surgical-associated therapy and 40.9% of the non-surgical cases (OR 1.1; 95% CI 0.4-3.2; p=0.96). This result could be due to the higher incidence of embolic events in the early course of FE.
Even in a multivariate analysis adjusted for gender, age (two blocks; ≥ or < than 65 years), combined surgical Table 2) .
Discussion
The first case of endocarditis due to C. parapsilosis was reported in 1940 [8] . In the years that followed, this agent was predominantly reported as an etiology of endocarditis, notably in IVD users [9] . However, C. parapsilosis is now considered to be an important emerging pathogen of invasive candidiasis, only surpassed by C. albicans [10] , and this will probably have consequences on FE microbiology in the near future [11, 12] . C. parapsilosis strains associated with invasive disease are more likely to produce biofilm structures [13] that are morphologically different from those produced by C. albicans [14] . Recent changes in fungal epidemiology may also be related to the wide use of azoles in combination with the new prophylactic and therapeutic strategies for fungal infections. More specifically, there is a consensus that the percentage of Candida non-albicans species accounting for nosocomial Candida infections is increasing, in part due to the widespread use of fluconazole [15] . The most probable source of infection in the outbreaks of C. parapsilosis infective endocarditis reported to date was determined to be intraoperative contamination (e.g. cardiac bypass equipment, tears in surgical gloves worn by carrier surgeons) [16, 17] .
The core findings of this review reveal that the aortic valve was the most commonly involved valve, with 42.5% of cases occurring in native valves. The most common predisposing factor in patients with native valve involvement was IVD use. Overall mortality among these patients was as high as 41.7%, with a lower mortality among those treated with adjuvant surgery. Only five cases treated with new antifungal drugs have been reported to date, which precludes the drawing of any firm conclusion on their role in the treatment of C. parapsilosis endocarditis.
Only four (5.7%) patients did not present any predisposing factor for C. parapsilosis endocarditis. However, Rubinstein and Lang reported that as high as 12% of patients presenting with FE have no identifiable predisposing factors [18] . In general, the predisposing factors observed were similar to those of patients with endocarditis due to C. albicans [19] . A comparison of C. albicans and C. parapsilosis endocarditis cases shows that FE due to these pathogens rarely originates without a predisposing factor and occurs more frequently in prosthetic valves. In addition, a history of IVD use was present in 20% of patients with C. parapsilosis infection. In contrast, C. albicans seems to be less frequently associated with IVD use and is observed predominantly in patients with underlying abnormal valves, mostly with rheumatic disease (Table 1) . Our data suggest also that C. parapsilosis is more prevalent than C. albicans in patients receiving parenteral nutrition (Table 1) .
Embolic and/or hemorrhagic complications were present in 43.8% of patients, most commonly as cerebral thromboembolic events, which is in accordance with the incidence rate reported by Ellis et al. [4] . In general, the occurrence of embolic events in patients with fever should always be seen as a potential diagnostic of infective endocarditis. In particular, a fungal etiology must be considered, given the high likelihood of thromboembolic events reported in these cases [20] .
Survival in patients with FE is poor and barely exceeds 50% [18] . Although C. parapsilosis endocarditis has been associated with a higher mortality when compared to endocarditis caused by other Candida species [19] , this could not be confirmed in our comparison with C. albicans cases ( Table 1) .
The ideal treatment for Candida endocarditis has not been formally tested in prospective randomized controlled studies. In the present review, combined surgical and medical therapy was associated with a lower mortality rate. In clinical practice, surgery is generally regarded as the standard treatment for FE. The American College of Cardiology (ACC) and The American Heart Association (AHA) guidelines stipulate surgical indications for FE (Class I recommendation). In addition, the recent Infectious Diseases Society of America (IDSA) guidelines on Candida endocarditis recommend that it should be treated by valve replacement, either for native or prosthetic valves [21] . Unfortunately, the heterogeneity of the population affected, allied to the relative rarity of FE, makes the performance of prospective studies impractical [4] .
Retrospective studies based on well-documented cases may be a feasible alternative. In their recent meta-analysis, Steinbach et al. suggest that patients who underwent combined surgical and medical therapy may have presented a lower mortality rate (OR 0.56; 95% CI 0.16-1.99). A higher [19] . However, methodological limitations should be considered when analyzing these results. For example, in very critically ill patients, a surgical procedure may be precluded, thus leading to a falsely higher mortality in the group with medical treatment alone. Moreover, a high number of patients with FE probably underwent surgery because endocarditis due to these agents are more frequently related per se to the classical indications for surgical treatment, such as thromboembolic events and the presence of large vegetations [22] . In the present review, thromboembolic events may have commonly indicated a surgical procedure, which explains why operated patients did not present a lower incidence of this complication in a cross-sectional analysis. Finally, isolated reports show that a single medical treatment for Candida endocarditis may be sufficient -in particular if the most potent and less toxic antifungal drugs are used [23] .
We observed a lower mortality rate among patients that underwent adjuvant surgery. Multivariate analysis revealed that this tendency persisted even with adjustment for type of valve (native or prosthetic), gender and age (≥ or < than 65 years). However, there was a lack of data for determining if patients treated with surgery had more severe disease and also on the delay between the diagnosis of endocarditis and the surgical procedure.
Since the mid-1990s, new antifungal drugs, such as second-generation triazoles (voriconazole and posaconazole), have become available which are well tolerated and active against fluconazole-less susceptible or fluconazoleresistant Candida species and which reach high body tissue concentrations, including in the central nervous system. Echinocandins (caspofungin, anidulafungin and micafungin), which have an innovative mechanism of action, are rapidly fungicidal for Candida species and are rarely associated with adverse events [24] . They present a good activity in the biofilm, which could be considered of interest in terms of FE in patients with prosthetic valves. Candida parapsilosis is less susceptible to echinocandins, but the clinical impact of the in vitro results have still to be evaluated [25] . However, apart from the lack of well-controlled clinical studies using these new compounds, high costs and the risk of resistance among fungal species are potential concerns for their widespread use. An early diagnosis allied to rapid and efficient treatment may potentially improve the outcome of FE.
This study presents some of the limitations that are common to retrospective studies. First, there is an important heterogeneity among included patients, and the clinical management of cases was not uniform. Second, data on patients treated with the new antifungal compounds are scarce, thus precluding any definitive conclusion. Finally, given that some of the relevant information is lacking in the reports, the retrospective analysis of treatments with the aim of comparing single medical or combined medical plus surgical treatment remains limited.
Conclusions
More experience is required with the use of newer antifungal agents in the treatment of C. parapsilosis endocarditis. These drugs may permit more efficient therapy since they are related to a higher efficacy and fewer side effects. As a result, the indication for surgical therapy may be reduced. Prospective randomized studies are required to answer these questions, although their feasibility is uncertain. 
